FKW00GA explained

Routes Of Administration:Oral
Class:Serotonin 5-HT1A receptor partial agonist; Serotonin 5-HT2A receptor antagonist
Synonyms:FKW-00GA; TGW00AA; TGW-00AA; TGWOOAA; TGW-OOAA

FKW00GA, also known as TGW00AA, is a serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist which is under development for the treatment of generalized anxiety disorder, social phobia (social anxiety disorder), and sexual dysfunction.[1] [2] [3] [4] [5] [6] It is taken by mouth.

As of June 2021, FKW00GA is in phase 2 clinical trials for generalized anxiety disorder, social phobia, and sexual dysfunction. It has been in phase 2 clinical trials since at least 2018. The drug is under development by Fabre-Kramer Pharmaceuticals. FKW00GA is a small molecule, but its chemical structure does not yet seem to have been released.

Notes and References

  1. Web site: FKW 00GA . AdisInsight . 15 June 2021 . 29 October 2024.
  2. Web site: Delving into the Latest Updates on TGW00AA with Synapse . Synapse . 19 September 2024 . 29 October 2024.
  3. Sartori SB, Singewald N . Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders . Pharmacology & Therapeutics . 204 . 107402 . December 2019 . 31470029 . 10.1016/j.pharmthera.2019.107402 . free .
  4. Farmer M, Yoon H, Goldstein I . Future Targets for Female Sexual Dysfunction . The Journal of Sexual Medicine . 13 . 8 . 1147–1165 . August 2016 . 27436073 . 10.1016/j.jsxm.2016.05.016 .
  5. Fagan HA, Baldwin DS . Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions . Expert Review of Neurotherapeutics . 23 . 6 . 535–548 . June 2023 . 37183813 . 10.1080/14737175.2023.2211767 .
  6. Staroń J, Bugno R, Hogendorf AS, Bojarski AJ . 5-HT1A receptor ligands and their therapeutic applications: review of new patents . Expert Opinion on Therapeutic Patents . 28 . 9 . 679–689 . September 2018 . 30124346 . 10.1080/13543776.2018.1514011 .